Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of the Combination of Glofitamab, Venetoclax and Lenalidomide in Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

NCT05861050 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT05861050
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05861050 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of the Combination of Glofitamab, Venetoclax and Lenalidomide in Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1/2
Overall status
Suspended
Start date
August 10, 2023
Completion date
February 1, 2027
Enrollment
50 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

blastoid variant mantle cell lymphoma, mantle cell lymphoma, pleomorphic variant mantle cell lymphoma